Skip to main content
OpenTrials
Completed

NCT Number: NCT02552108

A Single-Component CBT for GAD

Generalized Anxiety Disorder (GAD) is a chronic condition that is characterized by excessive and uncontrollable worry and anxiety. In Canada, 3 to 4% of the population suffer from GAD at any point in time. These individuals have a lowered quality of life and are at risk for many medical conditions such as coronary heart disease and cancer. Research suggests that both pharmacological and psychological approaches are effective for treating GAD in the short-term; however, psychological treatments appear to offer the greatest long-term benefits. There exist a number of effective psychological treatments for GAD, most of which fall into the category of cognitive-behavioural therapy or CBT. In the 1990s, a group of Canadian investigators developed a CBT protocol for GAD that included four components. Data from five clinical trials suggest that one of the four components is particularly important for treatment success: experiencing uncertainty rather than avoiding it in everyday life. Stated differently, learning to tolerate and deal with uncertainty appears to be the key to decreasing worry and anxiety. Given this finding, the investigators have developed a new treatment that exclusively targets intolerance of uncertainty: Behavioural Experiments for Intolerance of Uncertainty or BE-IU. The goal of the current proposal is to test the efficacy of BE-IU by comparing it to a Waiting List (WL) control condition. A total of 50 participants with a primary diagnosis of GAD will be randomly assigned to either BE-IU or WL and will be assessed at 5 time points ranging from pre-treatment to 12-month follow-up. The conditions will be compared in terms of treatment efficacy and mechanisms. The investigators will also examine the predictors of change during the 12-months following treatment. The proposed study will produce data on the efficacy and mechanisms of a treatment for GAD that is less costly, less complex and easier to disseminate than treatments that are currently available.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Université du Québec en Outaouais

Gatineau, Quebec, J8X 3X7, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • at least 18 years of age; 2) principal diagnosis of GAD; 3) no change in medication type or dose in 4 to 12 weeks before study entry (4 weeks for benzodiazepines, 12 weeks for antidepressants and hypnotics); 4) willingness to keep medication status stable while participating in the study; 5) no use of herbal products known to have CNS effects in the 2 weeks before study entry; 6) no evidence of suicidal intent (based on clinical judgement); 7) no evidence of current substance abuse, current or past schizophrenia, bipolar disorder or organic mental disorder; 8) no current participation in other trials; 9) no concurrent psychotherapy during treatment phase of trial; 10) no evidence of anxiety symptoms due to a general medical condition based on clinical judgement (e.g., clinical hyperthyroidism, hypoglycaemia, anaemia).

Exclusion criteria

-

Treatment and study plan

Behavioural experiments for intolerance of uncertainty (BE-IU)

Behavioral

Other names: CBT

Primary outcomes

  1. Clinician's Severity Rating (CSR) of Anxiety Disorders Interview Schedule (ADIS)

    Time frame: 12 weeks

    Structured diagnostic interview

Secondary outcomes

  1. Penn State Worry Questionnaire (PSWQ)

    Time frame: 12 weeks

    Self-report questionnaire

  2. Worry and Anxiety Questionnaire (WAQ)

    Time frame: 12 weeks

    Self-report questionnaire

  3. Beck Anxiety Inventory (BAI)

    Time frame: 12 weeks

    Self-report questionnaire

  4. Beck Depression Inventory-II (BDI-II)

    Time frame: 14 weeks

    Self-report questionnaire

Other outcomes

  1. Intolerance of Uncertainty Scale (IUS)

    Time frame: 14 weeks

    Self-report questionnaire

  2. Safety Behaviours Questionnaire (SBQ)

    Time frame: 14 weeks

    Self-report questionnaire

  3. Heart rate variability (HRV)

    Time frame: 14 weeks

    Heart rate monitoring with chest strap and Polar watch

  4. Acceptance and Action Questionnaire-2 (AAQ-2)

    Time frame: 14 weeks

    Self-report questionnaire

  5. Pain Catastrophizing Scale (PCS)

    Time frame: 14 weeks

    Self-report questionnaire

  6. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: 14 weeks

    Self-report questionnaire

Sponsors and collaborators

Lead sponsor

Universite du Quebec en Outaouais

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Concordia University, Montreal
  • University College, London

Registry information

Official study title

Behavioural Experiments for Intolerance of Uncertainty: A Single-Component Treatment for Generalized Anxiety Disorder

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Sep 16, 2015
Registry last updated
Jun 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.